Sigilon Therapeutics Inc Ordinary Shares SGTX Stock Quote
Morningstar‘s Stock Analysis SGTX
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile SGTX
Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. Its lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.